TP53 and breast carcinoma: For example, in mammary carcinoma p53 mutations have been associated with impaired clinical outcome in primary patients [143], whereas the histopathological detection of p53 expression by antibody staining was associated with beneficial outcomes selectively in HER2+ breast cancer [144].